SVS Medical LLC

Following two decades of revolutionary and groundbreaking developments in cosmetic and pharmaceutical packaging device development, including the globally acclaimed Single Vial System (SVS) technology, Prof. Dr. S Tsakas II, along with his father Prof. Dr. S Tsakas Sr., announces today some exciting news and updates from the scientific partnership that has been in operation since the early 1990s. Recently, the SVS technology has been endorsed, sponsored and funded by the Bill & Melinda Gates Foundation, World Health Organization, Prince's Trust, Scottish Enterprise and the Royal Society of Edinburgh for its ability to deliver twice as many medicines at half the cost worldwide.

SVS is exempt from clinical trials and unique registrations with the US FDA, European EMA and UK MHRA as well as exempt from CE certification through both the UK and EU. Moreover, it is merely a storage and reconstitution technology as opposed to a final product that will be used to deliver the actual medicines to the patient. As such, we are cleared for market launch immediately upon proving Stability and Non-Inferiority of the API within our technology.

Key Highlights

  Funded and endorsed by Bill & Melinda Gates Foundation, World Health Organization, Royal Society of Edinburgh, Prince’s Trust and Scottish Enterprise

  Pilot Batches of Fully Functional SVS available by September 2016

  Global Portfolio of Intellectual Property including Granted Patents & Trademarks

  SVS offers the potential to deliver twice as many medicines at half the cost worldwide

  Parenteral SVS is the pilot with ensuing Inhalation, Oral & Ocular SVS in the pipeline

  Seeking Partner Pharmaceutical Companies to Pilot Test SVS with API of choice

Primary Applications

  Vaccines

  Antidotes

  Antibiotics

  Oncology Treatments

  Insulin Treatments

  Medical Defense

  Hormone Treatments 

117 Manning Street
Hudson, MA 01749
[email protected]